SEC Form 4 · accession 0001567619-18-003536

Gritstone Oncology, Inc. · GRTS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director · 10% Owner

Period of report

Oct 2, 2018

Accepted (ET)

Oct 2, 2018 · 5:26 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001656634

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F3	Oct 2, 2018	C	3,102,934	—	A	3,102,934	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Convertible Preferred Stock^F3,F1	—	Oct 2, 2018	C	2,173,912	D	—	—	Common Stock	2,173,912	0	I
Series B Convertible Preferred Stock^F3,F2	—	Oct 2, 2018	C	929,022	D	—	—	Common Stock	929,022	0	I

F1The Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
F2The Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
F3Consists of the shares held by The Column Group II, LP. The Column Group II GP, LP is the general partner of The Column Group II, LP. The Reporting Person is a managing partner of The Column Group II GP, LP and may be deemed to have shared voting and investment power with respect to the shares. He disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.